Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients

Journal of Translational Medicine

Kota Okinaga¹  Yusuke Nakamura²  Tadashi Ikeda¹  Takuya Tsunoda³  Koji Yoshida³  Kazuyoshi Takeda⁴  Noriyuki Matsutani¹  Yoshibumi Ikeda¹  Masahiro Horikawa¹  Etsushi Ogawa¹  Taisuke Inoue¹  Junko Tamura¹  Tsuyoshi Inaba¹  Ryoji Fukushima¹  Hisae Iinuma¹ 

[1] Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan;The University of Chicago, Chicago, IL, USA;OncoTherapy Science Incorporation, Research and Development Division, Kanagawa, Japan;Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan

关键词: Phase I clinical trial;    CTL;    Esophageal cancer;    Chemoradiation therapy;    Cancer vaccine;   

Others  :  1148922
DOI  :  10.1186/1479-5876-12-84

 received in 2013-11-21, accepted in 2014-03-13,  发布年份 2014

【 摘 要 】

Background

Chemoradiation therapy (CRT) has been widely used for unresectable esophageal squamous cell carcinoma (ESCC) patients. However, many patients develop local recurrence after CRT. In this study, we hypothesized that the immunotherapy by peptide vaccine may be effective for the eradication of minimal residual cancer cells after CRT. This study was conducted as a phase I clinical trial of multiple-peptide vaccine therapy combined with CRT on patients with unresectable ESCC.

Patients and methods

HLA-A*2402 positive 11 unresectable chemo-naïve ESCC patients were treated by HLA-A*2402-restricted multi-peptide vaccine combined with CRT. The peptide vaccine included the 5 peptides as follows; TTK protein kinase (TTK), up-regulated lung cancer 10 (URLC10), insulin-like growth factor–II mRNA binding protein 3 (KOC1), vascular endothelial growth factor receptor 1 (VEGFR1) and 2 (VEGFR2). CRT consisted of radiotherapy (60 Gy) with concurrent cisplatin (40 mg/m²) and 5-fluorouracil (400 mg/m²). Peptide vaccines mixed with incomplete Freund’s adjuvant were injected subcutaneously once a week on at least 8 occasions combined with CRT.

Results

Vaccination with CRT therapy was well-tolerated, and no severe adverse effects were observed. In the case of grade 3 toxicities, leucopenia, neutropenia, anemia and thrombocutopenia occurred in 54.5%, 27.3%, 27.3% and 9.1% of patients, respectively. Grade 1 local skin reactions in the injection sites of vaccination were observed in 81.8% of patients. The expressions of HLA class I, URLC10, TTK, KOC1, VEGFR1 and VEGFR2 antigens were observed in the tumor tissues of all patients. All patients showed peptide-specific cytotoxic T lymphocytes responses in at least one of the 5 kinds of peptide antigens during the vaccination. Six cases of complete response (CR) and 5 cases of progressive disease (PD) were observed after the 8^th vaccination. The 4 CR patients who continued the peptide vaccination experienced long consistent CR for 2.0, 2.9 4.5 and 4.6 years.

Conclusions

A combination therapy of multi-peptide vaccine with CRT can successfully be performed with satisfactory levels of safety, and application of this combination therapy may be an effective treatment for patients with unresectable ESCC.

Trial registration

ClinicalTrial.gov, number NCT00632333.

【 授权许可】

   
2014 Iinuma et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Editorial Board of the Cancer Statistics in Japan (Ed): Cancer statistics in Japan 2013 Tokyo: Foundation for Promotion of Cancer Research; 2013.
• [2]Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H: Surgery plus chemotherapy compared with surgery alone for localize squamous cell carcinoma of the thoracic esophagus: a Japan clinical oncology group study–JCOG9204. J Clin Oncol 2003, 21:4592-4596.
• [3]Akiyama H, Tsurumaru M, Udagawa H, Kaijiyama Y: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994, 220:364-372.
• [4]Shitara K, Muro K: Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives. Gastrointest Cancer Res 2009, 3:66-72.
• [5]Ohtsu A: Chemoradiotherapy for esophageal cancer: current status and perspective. Int J Clin Oncol 2004, 9:444-450.
• [6]Le Prise E, Etienne PL, Meunier B, Maddern G, Hassel MB, Gedouin D, Boutin D, Campion JP, Launois B: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994, 73:1779-1784.
• [7]Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H: Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG Trial (JCOG 9906). Int J Radiat Oncol Biol Phys 2011, 81:684-690.
• [8]Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M: Phase II studyofcisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a japan esophageal oncology group (JEOG)/japan clinical oncology group trial (JCOG9516). Jpn J Clin Oncol 2004, 34:615-619.
• [9]Akutsu Y, Matsubara H: Perioperative management for the prevention of postoperative pneumonia with esophageal surgery. Ann Thorac Cardiovasc Surg 2009, 15:280-285.
• [10]Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JP, Lord EM: Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005, 174:7516-7523.
• [11]Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L: Toll-like resceptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
• [12]Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, Andr’e F, Tursz T, Kroemer G, Zitvogel L: The interaction between HMGB1 and TLR4 distates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007, 220:47-59.
• [13]Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX: Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
• [14]Chamoto K, Takeshima T, Wakita D, Ohkuri T, Ashino S, Omatsu T, Shirato H, Kitamura H, Togashi Y, Nishimura T: Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio-and immune-resistant lung carcinoma cells. Cancer Sci 2009, 100:934-939.
• [15]Emens LA, Jaffee EM: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005, 65:8059-8064.
• [16]Shurin GV, Tourkova IL, Kaneno R, Shurin MR: Chemotherapeutic agents in non cytotoxic concentrations increase antigen presentation by dendric cells via in IL-12-dependent mechanisms. J Immunol 2009, 183:137-141.
• [17]Correale P, Aquino A, Giuliani A, Pellegrini M, Micheli L, Cusi MG, Nencini C, Petrioli R, Prete S, De Vecchis L, Turriziani M, Giorgi G, Bonmassar E, Francini G: Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A (*) 02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Caner 2003, 104:437-445.
• [18]Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H: Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007, 98:1803-1808.
• [19]Yamabuki T, Daigo Y, Kato T, Hayama S, Tsunoda T, Miyamoto M, Ito T, Fujita M, Hosokawa M, Kondo S, Nakamura Y: Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol 2006, 28:1375-1384.
• [20]Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H: Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 2005, 65:4939-4946.
• [21]Ishizuka H, Tsunoda T, Wada S, Yamaguchi M, Shibuya M, Tahara H: Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vasclar endothelial growth factor receptor 1. Clin Cancer Res 2006, 12:5841-5849.
• [22]Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H: Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009, 100:1502-1509.
• [23]Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R, Matsubara H, Ohira M, Baba H, Natsugoe S, Kitano S, Takeda K, Yoshida K, Tsunoda T, Nakamura Y: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012, 10:141. BioMed Central Full Text
• [24]Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, Nakamura Y, Yamaue H: Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010, 101:433-439.
• [25]Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H: Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008, 99:1448-1454.
• [26]Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E: A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer 2011, 129:2836-2846.
• [27]Iwahashi M, Katsuda M, Nakamori M, Nakamura M, Naka T, Ojima T, Iida T, Yamaue H: Vaccination with peptides derived from cancer-testis antigen in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci 2010, 101:2510-2517.
• [28]Kamrava M, Bernstein MB, Camphausen K, Hodge JW: Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the three musketeers of just another quixotic combination? Mol BioSyst 2009, 5:1262-1270.
• [29]Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H, Nishimura T: Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res 2010, 70:2697-2706.
• [30]Akutsu Y, Matsubara H, Urashima T, Komatsu A, Sakata H, Nishimori T, Yoneyama Y, Hoshino I, Murakami K, Usui A, Kano M, Ochiai T: Combination of direct intratumoral administration of dendritic cell and irradiation induces strong systemic antitumor effect mediated by GRP94/gp96 against squamous cell carcinoma in mice. Int J Oncol 2007, 31:509-515.
• [31]Hattori T, Mine T, Komatsu N, Yamada A, Itoh K, Shiozaki H, Okuno K: Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 2009, 58:1843-1852.
• [32]Sato Y, Fujiwara T, Mine T, Shomura H, Homma S, Maeda Y, Tokunaga N, Ikeda Y, Ishihara Y, Yamada A, Tanaka N, Itoh K, Harada M, Todo S: Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci 2007, 98:1113-1119.
• [33]Märten A, Schmidt J, Ose J, Harig S, Abe U, Münter MW, Jäger D, Friess H, Mayerle J, Adler G, Seufferlein T, Gress T, Schmid R, Büchler MW: A randomized multicentre Phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival-CapRI-2. BMC Cancer 2009, 9:160.
• [34]Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines. 2011. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm182443.htm webcite